Novartis's canakinumab cut risks for heart attack survivors: study

ZURICH (Reuters) - Novartis's investigational medicine canakinumab cut cardiovascular risk for people who had survived a heart attack, the Swiss drugmaker said on Thursday, citing a late-stage study.